Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib for Reversal of Gastric Metaplasia
NCT04454476Phase 1Active, not recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trametinib in gastric intestinal metaplasia (IM), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Effectiveness of Trametinib in reversing metaplasia: changes in cell lineages at 12 months and Safety of Trametinib treatment: adverse events at 12 weeks. Started Nov 2022; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
gastric intestinal metaplasia (IM)
Beyond the preview
Go deeper on NCT04454476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454476.